Kevin Raidy News Today

Blue Owl Capital announced an agreement to acquire funds managed by Cowen Healthcare Investments (CHI)

Cowen Healthcare Investments closes $555.6M Cowen Healthcare Investments IV ("CHI IV" or the "Fund") to invest in life sciences companies.

CHI IV will invest primarily in mid- to late-stage life sciences opportunities.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

/PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range...

Aro Biotherapeutics, a Philadelphia, PA-based biotechnology company pioneering the development of tissue-targeted genetic medicines, closed an $88m Series A financing. The round was led by Northpond Ventures and Cowen Healthcare Investments, with participation from HealthCap, BVF Partners L.P., and Ridgeback Capital. Existing investors, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), BioMotiv, LLC, and Ionis Pharmaceuticals, Inc. In conjunction with the funding, Shaan Gandhi, M.D., D.Phil....

Neuron23, Inc., a South San Francisco, CA, and Munich, Germany-based early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, has launched backed by a combined $113.5m Series A and B financing. The round was comprised of $33.5m Series A financing from Westlake Village BioPartners and Kleiner Perkins, and $80m Series B financing led by Redmile Group. Additional Series B investors included Westlake Villag...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Neuron23™ Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group December 16, 2020 GMT SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 /PRNewswire/ -- Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced its launch backed...